- Redx Pharma said it had commenced a study for a cancer treatment with the first patient having now been dosed at The Christie in Manchester.

The treatment, RXC004, is a novel, oral, potent small molecule Porcupine inhibitor, which targets the Wnt pathway, an embryonic signalling pathway that is implicated in the maintenance of cancer stem cells in multiple cancer types.

RXC004 had now progressed into the dose-finding Phase 1 element of the study in patients with cancer. Once completed, the selected dose would then be used as a monotherapy in a larger number of patients with difficult to treat cancers.

Redx expected to report initial data from the 1a segment of the trial in the second half of 2018.

'We are very excited by the potential of RXC004 to make a major difference in cancer treatment,' chairman Iain Ross said.

'We believe that RXC004 has great potential to treat some very challenging cancers that currently have very poor prognosis and we look forward to updating the market on our progress.'

At 9:16am: [LON:REDX] Redx Pharma Plc share price was -0.5p at 16.5p

Story provided by